THE CHOICE OF TACTICS OF TREATMENT OF GIANT RETROSTERNAL DIFFUSE TOXIC GOITER IN ELDERLY AGE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Graves’ disease is one of the common causes of hyperthyroidism and can be associated with an increase in the size of the thyroid gland, a goiter, endocrine ophthalmopathy and pretybial myxedema. In Europe and Russia , the main method of treatment of diffuse toxic goiter includes the use of antithyroid drugs belonging to the group of thionamides. The duration of treatment, as a rule, is 18-24 months. Radioactive iodine therapy can also be used as a method of treatment, but the prevalence of this type of treatment varies considerably depending on the region and country of residence of the patient. The article presents the clinical experience of management of 79-year-old female patient with a giant diffuse toxic goiter and effective treatment of the disease by radioactive iodine therapy.

Full Text

Restricted Access

About the authors

I. B Zhurtova

Kabardino-Balkar State University n.a. Kh. M. Berbekov

Email: zhin07@mail.iu
MD, Associate Piofessoi at the Department of Faculty Therapy and Occupational Diseases Nalchik

References

  1. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. М., 2009;422.
  2. Свириденко Н.Ю., Беловалова И.М., Шеремета М.С., Табеева К.И., Ремизов О.В. Болезнь Грейвса и эндокринная офтальмопатия / Под ред. И.И. Дедова и Г.А. Мельниченко. М., 2012.
  3. Toft A.D. Subclinical Hyperthyroidism. N. Eng. J. Med. 2001;345(7):512-16.
  4. Wallaschofski H., Orda C., Georgi P., Miehle K., Paschke R. Distinction Between Autoimmune and Non-Autoimmune Hyperthyroidism by Determination of TSH-Receptor Antibodies in Patients with the initial Diagnosis of Toxic Multinodular Goiter. Hormone and Metabolic Research. 2001;33(8):504-7.
  5. Singh I., Hershman J.M. Pathogenesis of Hyperthireiodism. Compr. Physiol. 2016;7:67-79.
  6. Menconi F., Marccci C., Marino M. Diagnosis and classification of Graves' disease. Autoimmun Revews. 2014;13(4W5):398W402.
  7. Фадеев В.В., Абрамова Н.А., Прокофьев С.А., Гитель Е.П., Мельниченко Г.А., Дедов И.И. Антитела к рецептору ТТГ в дифференциальной диагностике токсического зоба. Проблемы эндокринологии. 2005;51(4):10-8.
  8. Fadeyev V. Clinical Aspects of Thyroid Disorders in the Elderly. Thyroid int. 2007;3:3-15.
  9. Bahn R.S., Burch H.B., Cooper D.S., Garber J.R., Greenlee M.C., Klein I., et al. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
  10. Ginsberg J. Diagnosis and management of Graves' disease. Can. Med. Association J. 2003;168(5):575-85.
  11. Weetman A.P. Graves' Disease. N. Eng. J. Med. 2000;343(17):1236-48.
  12. Laurberg P. Multinodular goiter. Thyroid international. 2000;3:1-12.
  13. Pinchera A., Wiersinga W.M. Recommendations for the assessment of therapeutic outcome of Graves' disease in clinical trials. in: Prummel M.F., Wiersinga W.M., Mourits M.Ph., Heufelder A.E., eds. Recent developments in Graves' ophthalmopathy. London: Kluwer Academic Publishers, 2000.
  14. Клинические рекомендации по диагностике и лечение тиреотоксикоза Американской Тиреоидной Ассоциации и Американской Ассоциации Клинических Эндокринологов. Перевод и комментарии В.В. Фадеева, Е.А. Корселадзе. 2011. Режим доступа: http://www. thyronet.rusmedserv.com/.
  15. Piantanida E., Sassi L., Gallo D., Spreafico E., Tanda M.L., Bartalena L. Outcome Prediction of Treatment of Graves' Hyperthyreoidism with Antithyreoid Drugs. Horm. Metab. Res. 2015;47:767-72.
  16. Lal G., Ituarte P., Kebebew E., Siperstein A., Duh Q.-Y., Clark O.H. Should Total Thyroidectomy Become the Preferred Procedure for Surgical Management of Graves' Disease? Thyroid. 2005;15(6):569-74.
  17. Lepner U., Seire I., Palmiste V., Kirsimägi Ü. Surgical treatment of Graves' disease: subtotal thyroidectomy might still be the preferred option. Medicina (Kaunas, Lithuania). 2008;44(1):22-6.
  18. Werga-Kjellman P., Zedenius J., Tallstedt L., Träisk F., Lundell G., Wallin G. Surgical Treatment of Hyperthyroidism: A Ten-Year Experience. Thyroid. 2001;11(2):187-92.
  19. Фадеев В.В., Дроздовский Б.Я., Гусева Т.Н., Гарбузов П.И., Бузиашвили И.И., Мельниченко Г.А. Отдаленные результаты лечения токсического зоба радиоактивным I131. Проблемы эндокринологии. 2005;51(1):3-9.
  20. Bartalena L., Tanda M.L., Piantanida E., Lai A. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 2005;153(1):13-4.
  21. Bahn R.S., Burch H.B., Cooper D.S., Garber J.R., Greenlee M.C., Klein I., Laurberg P., McDougall I.R., Montori V.M., Rivkees S.A., Ross D.S., Sosa J.A., Stan M.N. Hyperthyreoidism and Other Causes of Thyreotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21.
  22. Ma C., Xie J., Wang H., Li J., Chen S. Radioiodine therapy versus antithyreoid medications for Graves' disease. Thyroid. 2016;3.
  23. Бебезов Б.Х., Нуралиев М.А., Какчекеева Т.Т., Салиева Б.Р., Чазымов Р.М. Тактика лечения диффузного токсического зоба. Клин. медицина. 2013:9:61-6.
  24. Weetman A.P. Pathogenesis, diagnosis and treatment of Graves' disease. Thyroid int. 2003;(2):82-5.
  25. Фадеев В.В., Мельниченко Г.А. Болезнь Грейвса: диагностика, современные средства лечения. Врач. 2005;12:35-9.
  26. Esfahani A.F., Kakhki V.R., Fallahi B., Eftekhari M., Beiki D., Saghari M., et al. Comparative evaluation of two fixed doses of 185 and 370 MBq I131, for the treatment of Graves' disease resistant to antithyreoid drugs. Hellenic J. Nucl. Med. 2005;8(3):158-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies